Differentiated Vulvar Intraepithelial Neoplasia, Vulvar High Grade Squamous Intraepithelial Lesion, Vulvar Intraepithelial Neoplasia
Conditions
Keywords
Vulvar Intraepithelial Neoplasia, Vulvar High Grade Squamous Intraepithelial Lesion, Photodynamic diagnosis, Metvixia, Differentiated vulvar intraepithelial neoplasia
Brief summary
This study is a single-center propsective clinical trial to assess the ability of fluorescence techniques to mark high-grade vulvar intraepithelial neoplasias including high-grade vulvar squamous intraepithelial lesions and differentiated vulvar intraepithelial neoplasias following 3 hours Metvixia application.
Interventions
DRUGMetvixia Topical Cream
Metvixia is applied with a spatula, in a thick layer, to clinically visible lesions and all over the vulva. After applying the cream, the area will be covered with a bandage which should remain in place for 3 hours. After 3 hours of application, the bandage and the cream will be carefully removed. The application area will be cleaned and then immediately exposed to a continuous spectrum of light at a wavelength of 405 nm by a xenon lamp. The most fluorescent areas will be identified. Then in white light, the practitioner will perform at least two biopsies under non-topical local anesthesia in the area of application of Metvixia®: one in the fluorescent area and one in the non-fluorescent area. If there is no fluorescent labeling, two samples will be taken from two different non-fluorescent areas. In the event that all the zone is fluorescent , two samples will be taken from two different fluorescent zones.
Sponsors
Institut de Cancérologie de Lorraine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient aged 18 and over, * With isolated high-grade vulvar intraepithelial neoplasia OR associated with invasive cancer proven histologically by biopsy * Naive of any vulvovaginal treatment (surgery or radiotherapy) * No metastases * WHO \<or equal to 3 * Contraception method for women of childbearing potential * Patient affiliated to the social security scheme * Patient who understood, signed and dated the information note and the * consent form, * Patient able and willing to follow all study procedures in accordance with the protocol.
Exclusion criteria
* History of hypersensitivity to the active substance methyl aminolevulinate or to any of the components of the drug (including peanut oil and refined almond oil), soybean or peanut * Ulceration or hyperpigmented lesions of the vulva * Patient with porphyria * Any previous vulvovaginal treatment (surgery or radiotherapy) * Metastatic disease * Patient undergoing treatment for any other invasive cancer * Pregnant, likely to be or breastfeeding patient * Patient deprived of liberty or under guardianship (including guardianship) * Inability to undergo medical monitoring of the trial for geographic, social or psychological reasons. * Patient already included in another therapeutic trial with an experimental molecule, * Associated pathology that may prevent the patient from receiving METVIXIA application and light exposure.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the success of the photodynamic diagnosis | 14 days (+/- 4 days) after the photodiagnosis | Percentage of patients for whom the procedure successfully demonstrated high-grade vulvar intraepithelial neoplasias in fluorescence confirmed by biopsy. A patient will be considered successful if the presence or absence of fluorescence is consistent with the anatomo-pathological result, that means if her sample in the fluorescent area is positive in pathology and her sample in the non-fluorescent area is negative in anatomo-pathology. For a patient with no fluorescent labeling, the pathological results of her two samples must be negative for the patient to be considered successful. For a patient where the entire area fluoresces, the anatomo-pathological result of her two samples must be positive for the patient to be considered successful. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity of the photodynamic diagnosis | 14 days (+/- 4 days) after the photodiagnosis | The sensitivity will correspond to the number of fluorescent zones among the positive zones in anatomopathology. |
| Specifity of the photodynamic diagnosis | 14 days (+/- 4 days) after the photodiagnosis | The specificity will correspond to the number of non-fluorescent zones among the negative zones in anatomo-pathology. |
| Intensity of flurescence evaluation | The day of the photo analysis with a specific software | The fluorescence intensity will be measured by the signal to noise ratio, also called SNR (Signal to Noise Ratio) on photographie |
| Tolerance evaluation | At inclusion, after applying the cream for 3 hours, before and immediately after the blue light exposition and at and the final study visite (14 days +/- 4 after the photodiagnosis) | The tolerance of the application will be assessed by the number of grade 3 to 5 toxicity. The toxicity will be evaluated using the CTCAE v5 scale (Common Terminology for Adverse Events). The different grade on this scale is 1 to 5 (1 correspond to a asymptomatic or mild symptome, 2 to moderate toxicity, 3 to severe or medically significant but not immediately life-threatening toxicity, 4 to life-threatening consequences or urgent intervention indicated and 5 to the death related to the toxicity. |
| Pain Evaluation | At inclusion, 1 hour after Metvixia application, before and immediately after the blue light exposition and at and the final study visite (14 days +/- 4 after the inclusion) | Pain will be assessed using a numerical scale from 0 to 10 (0 corresponds to no pain and 10 to maximum pain) |
Countries
France
Outcome results
None listed